Engel Law PLLC is investigating whether fair value to Decibel Therapeutics, Inc. (NASDAQ: DBTX) shareholders will result from the proposed acquisition of Decibel by Regeneron Pharmaceuticals, Inc. for (i) $4.00 in cash and (ii) one non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones for each Decibel share.
The Firm’s investigation concerns:
(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.